

1 Gastroesophageal reflux disease is associated with differences in the allograft
2 microbiome, microbial density and inflammation in lung transplantation.

3 Pierre H.H. Schneeberger^{1,2*} and Chen Yang Kevin Zhang^{1,3*}, Jessica Santilli^{1,2}, Bo
4 Chen⁴, Wei Xu⁴, Youngho Lee^{1,2}, Zonelle Wijesinha^{1,2}, Elaine Reguera-Nuñez^{1,2},
5 Noelle Yee^{1,2}, Musawir Ahmed^{2,3}, Kristen Boonstra³, Rayoun Ramendra³, Courtney
6 W. Frankel⁵, Scott M. Palmer⁵, Jamie L. Todd⁵, Tereza Martinu^{1,2,3,§}, Bryan
7 Coburn^{1,2,§}

8 1 Departments of Medicine and Laboratory Medicine & Pathobiology, University of
9 Toronto, Toronto, Canada, 2 Department of Medicine, University Health Network,
10 Toronto, Canada, 3 Toronto Lung Transplant Program, University Health Network,
11 Toronto, Canada, 4 Department of Biostatistics, Princess Margaret Cancer Centre,
12 University of Toronto, Toronto, Canada, 5 Department of Medicine, Duke University
13 Medical Center, Durham, NC, USA.

14 Corresponding authors: Bryan Coburn & Tereza Martinu, Department of Medicine,
15 University Health Network, 585 University Ave, M5G 2N2, Toronto, Canada.

16 Tel.: +1 416 340-4800, E-mails: bryan.coburn@utoronto.ca & tereza.martinu@uhn.ca

17

18 * These authors contributed equally

19 § These authors contributed equally

20

21 E-mail addresses:

22 PHHS pierre.schneeberger@swisstph.ch

23 CYKZ cykevin.zhang@mail.utoronto.ca

24 JS jessica.santilli@mail.utoronto.ca

25 BC Bo.Chen@uhnresearch.ca

26 XW Wei.Xu@uhnresearch.ca
27 YL dopa25@gmail.com
28 ZW zonelle.wijesinha@mail.utoronto.ca
29 ERN ereguera1983@gmail.com
30 NY Noelle.Yee@uhnresearch.ca
31 MA musawir.ca@gmail.com
32 KB kristenboonstra1@gmail.com
33 RR rayoun.ramendra@uhn.ca
34 CWF courtney.frankel@duke.edu
35 SMP scott.palmer@duke.edu
36 JLT jamie.todd@duke.edu
37 TM tereza.martinu@uhn.ca
38 BC bryan.coburn@utoronto.ca

39

40 Keywords:

41 lung microbiota; gastroesophageal reflux disease, bronchoalveolar lavage, chronic
42 lung allograft dysfunction, longitudinal microbial data, lung allograft inflammation

43

44 **Abstract**

45 **Rationale:** Gastroesophageal reflux disease (GERD) may affect lung allograft
46 inflammation and function through its effects on allograft microbial community
47 composition in lung transplant recipients.

48 **Objectives:** Our objective was to compare the allograft microbiota in lung transplant
49 recipients with or without clinically diagnosed GERD in the first post-transplant year,

50 and assess associations between GERD, allograft microbiota, inflammation and
51 acute and chronic lung allograft dysfunction (ALAD/CLAD).

52 **Methods:** 268 bronchoalveolar lavage samples were collected from 75 lung
53 transplant recipients at a single transplant centre every 3 months post-transplant for 1
54 year. Ten transplant recipients from a separate transplant centre provided samples
55 pre/post-anti-reflux Nissen fundoplication surgery. Microbial community composition
56 and density were measured using 16S rRNA gene sequencing and qPCR,
57 respectively and inflammatory markers and bile acids were quantified.

58 **Measurements and Main Results:** We observed three community composition
59 profiles (labelled community state types, CSTs 1-3). Transplant recipients with GERD
60 were more likely to have CST1, characterized by high bacterial density and relative
61 abundance of the oropharyngeal colonizing genera *Prevotella* and *Veillonella*. GERD
62 was associated with more frequent transition to CST1. CST1 was associated with
63 lower per-bacteria inflammatory cytokine levels than the pathogen-dominated CST3.
64 Time-dependant models revealed associations between CST3 and development of
65 ALAD/CLAD. Nissen fundoplication decreased bacterial load and pro-inflammatory
66 cytokines.

67 **Conclusion:** GERD was associated with a high bacterial density,
68 *Prevotella/Veillonella* dominated CST1. CST3, but not CST1 or GERD, was
69 associated with inflammation and early development of ALAD/CLAD. Nissen
70 fundoplication was associated with decreases in microbial density in BALF samples,
71 especially the CST1-specific genus, *Prevotella*.

72

73 **Introduction.**

74 Gastroesophageal reflux disease (GERD) is common after lung transplantation and is
75 characterized by reflux of gastric contents, including gastric acid, mucus, digestive
76 enzymes and bile acids. This refluxate can be aspirated by some patients, leading to
77 lung allograft injury and inflammation. Indeed, we recently reported an association
78 between GERD, levels of taurocholic acid (TCA, a bile acid) and inflammatory
79 markers in the bronchoalveolar lavage fluid (BALF), and acute lung allograft
80 dysfunction (ALAD) at 3-months post-transplant (1). The association of GERD and
81 chronic lung allograft dysfunction (CLAD) – the leading cause of death in the late
82 post-transplant period (2) – is inconsistent, however, with some, but not all studies
83 indicating GERD is a risk factor for CLAD (3, 4).

84 The composition of microbial communities in the lung allograft after transplantation
85 varies between individuals and is associated both with CLAD (5, 6) and acute
86 inflammation (7, 8). Composition of the allograft microbial community may follow
87 dynamics similar to those presented in the ecological concept of island biogeography
88 (9) in which community composition is the product of immigration and extinction rates
89 (10, 11). These rates can be affected by multiple factors including individual
90 characteristics such as proximity of the trachea to the oropharynx, and, potentially,
91 GERD.

92 The composition of allograft microbial communities is associated with distinct
93 patterns of soluble biomarkers in BALF, with communities dominated by
94 *Proteobacteria* or *Firmicutes* being associated with inflammation and *Bacteroidetes*
95 domination associated with markers of airway remodelling (7, 8). We reasoned that
96 allograft microbial community composition, GERD and inflammation may be
97 associated in the post-transplant period, and that models incorporating both GERD

98 and community composition may predict inflammation, ALAD and CLAD better than
99 models including only individual predictors.

100 To address this, we compared lung allograft microbial community composition from
101 BALF between individuals with and without GERD in the first year after transplant
102 and assessed GERD/microbial-community/inflammation associations, including
103 longitudinal comparisons. We assessed GERD and microbial community composition
104 as predictors of inflammation, ALAD, and CLAD in this cohort. Finally, we measured
105 changes in microbial density and inflammatory cytokines levels before and after
106 Nissen fundoplication in a secondary cohort of lung transplant recipients to determine
107 whether surgical treatment of GERD altered microbial density and inflammation.

108 **Results.**

109 **Cohort features.**

110 Baseline patient characteristics of the GERD cohort were comparable between
111 GERD and no-GERD patients (**Table 1**) and inclusion/exclusion criteria are reported
112 in **Figure S1**. Transbronchial biopsy pathology results (A-grades and B-grades),
113 BALF culture results, CLAD diagnoses, and follow-up times are reported for each
114 patient in **Figure S2**. Baseline characteristics of Nissen cohort patients are reported
115 in **Table 2**.

Characteristic	GERD (n=24)	no-GERD (n=51)	P value
Recipient age at transplant			0.23
Mean \pm SD	54 \pm 14	57 \pm 12	
Range	19–70	22–75	
Male, n (%)	14 (58)	29 (57)	1.00
Native lung disease, n (%)			0.98
Chronic Obstructive Pulmonary Disease	4 (17)	10 (20)	
Cystic Fibrosis	2 (8)	6 (12)	
Pulmonary Fibrosis	12 (50)	24 (47)	
Other	6 (25)	11 (22)	
Transplant type, n (%)			1.00
Single lung	3 (13)	7 (14)	
Double lung	24 (87)	44 (86)	

Donor recipient CMV status, n (%)			0.85
D-/R-	3 (13)	11 (22)	
D-/R+	7 (29)	14 (27)	
D+/R-	6 (25)	12 (24)	
D+/R+	8 (33)	14 (27)	
BAL samples available by time point, n			
3 months	23	51	
6 months	20	43	
9 months	20	49	
12 months	19	45	
24h pH impedance testing, n			
Total reflux episodes	8 (5-15)	66 (57-71)	<0.001
Proximal reflux episodes	5 (2-8)	38 (26-54)	<0.001

116 **Table 1.** Baseline patient characteristics of the main cohort.

Characteristic	Nissen cohort (n=10)
Recipient age at transplant	
Mean \pm SD	47 \pm 14
Range	18–65
Male, n (%)	2 (20)
Native lung disease, n (%)	
Chronic Obstructive Pulmonary Disease	3 (30)
Cystic Fibrosis	3 (30)
Pulmonary Fibrosis	0 (0)
Other	4 (40)
Days from transplant to Nissen, mean \pm SD	70 \pm 29

117 **Table 2.** Characteristics of patients undergoing Nissen fundoplication to treat GERD.

118 **Comparison of bacterial community composition in BALF between lung**
119 **transplant recipients with and without GERD**

120 We first assessed bacterial community composition by 16S rRNA gene sequencing
121 (**Figure 1**). Using a Bray-Curtis dissimilarity matrix, we identified three distinct
122 underlying community clusters, or community state types 1-3 (CST1-3, **Figure 1A**).
123 GERD cases and no-GERD controls had distinguishable community composition
124 distributions (PERMANOVA $P < 0.001$, **Figure 1B**) but GERD status explained only a
125 small amount of compositional variance ($R^2 = 0.013$). The proportion of GERD cases
126 with CST1 was greater than that of controls, while the proportion of CST2 was less
127 than controls ($P = 0.014$, OR for CST1 [95% CI] = 2.4 [1.2-4.4]) but a similar
128 proportion of patients in both groups presented CST3 ($P = 0.12$, OR for CST1 [95%
129 CI] = 1.7 [0.9-3.2], **Figure 1C**).

130 *Association with Bile Acids:* As previously reported (1), TCA was significantly
131 associated with GERD at 3 months post-transplant in this cohort. In this present
132 study, we assessed CST and bile acid associations at 3 months post-transplant. The
133 CSTs were not significantly associated with bile acid concentrations, but weakly trend
134 towards greater TCA and GCA concentrations in CST1 and CST3 (**Figure S3**).

135 Microbial community composition, bacterial density and within-sample (alpha)
136 diversity differed by CST (**Figure 2**). CST1 was characterized by the high relative
137 abundance of oropharyngeal taxa including *Prevotella* and *Veillonella*. The genera
138 *Streptococcus* and *Tanerella*, were significantly enriched in CST2, while CST3 was
139 characterized by an enrichment of genera with commonly pathogenic species
140 *Pseudomonas* and *Staphylococcus* (**Figure 2A**). The BALF CSTs were distinguished
141 most strongly by the genera *Prevotella*, *Veillonella*, *Streptococcus*, *Pseudomonas*,
142 and *Staphylococcus* with mean decreases of classification accuracy of 0.102, 0.041,
143 0.025, 0.02, and 0.018, in a random forest model that omitted these taxa,
144 respectively (model classification accuracy=82% and Cohen's Kappa=73.9%).

145 The median bacterial density (16S rRNA gene copies/mL BALF) was ~10-fold higher
146 in CST1 than in CST 2 or 3, as was the absolute abundance of the CST1-associated
147 genus *Prevotella* as measured by 16S rRNA gene and *Prevotella*-specific qPCR,
148 respectively (**Figure 2B**). Although taxonomic richness was highest in CST1,
149 composite (Shannon) diversity was lower than CSTs 2 and 3 due to the high relative
150 abundance of *Prevotella*. CST2 had the greatest evenness/lowest tendency towards
151 dominated communities, while CST3 was characterized by high variability in density,
152 diversity and taxonomic dominance, with many samples highly dominated by a single
153 taxon (**Figure 2C**). The most abundant genera in the highly dominated communities
154 in CST3 were *Staphylococcus* and *Pseudomonas*. Thus, CST1 seems to represent a

155 high-bacterial-density state dominated by oropharyngeal taxa, CST2 a low-density
156 state and CST3 a variable-density state commonly characterized by dominance with
157 pathogenic taxa. Although the proportion of samples in each CST differed by GERD
158 status, compositional differences between GERD and no-GERD samples within
159 CSTs were not observed.

160 *Longitudinal comparisons in the first post-transplant year.* We next assessed
161 whether bacterial density, alpha diversity, CST membership and their longitudinal
162 stability differed between GERD cases and no-GERD controls. Using a generalized
163 estimating equation (GEE) model, we assessed stability in bacterial density over time
164 and observed that GERD patients had significantly greater variability in microbial
165 density than controls (coefficient of correlation for cases: $\rho = 0.165$, $P = 0.332$ and for
166 controls $\rho = 0.153$, $P = 0.01$, a $P < 0.05$ indicating stability over time, **Figure 3A**).
167 Shannon diversity and Berger-Parker dominance were consistent over the first year
168 in controls ($\text{mean}_{\text{SDI}(\text{no-GERD})} = 2.35$, $\text{CI}_{95} [2.26-2.45]$; $\text{mean}_{\text{BP}(\text{no-GERD})} = 0.33$, CI_{95}
169 $[0.31-0.36]$). In GERD patients, both indices were significantly lower than controls at
170 3 months (MW; $\text{mean}_{\text{SDI}(\text{GERD})} = 1.98$, $\text{mean}_{\text{BP}(\text{GERD})} = 0.42$, $P = 0.007$ and 0.025 ,
171 respectively) but not at later timepoints ($\text{mean}_{\text{SDI}(\text{GERD})} (6-12\text{mts}) = 2.32$, $\text{CI}_{95} [2.18-$
172 $2.48]$; $\text{mean}_{\text{BP}(\text{GERD})} (6-12\text{mts}) = 0.33$, $\text{CI}_{95} [0.29-0.36]$, **Figure 3B**), indicating that
173 recovery of microbial diversity is delayed in patients with GERD.

174 Compositional variability over time was greatest in both groups at early sampling
175 intervals (3-6 months) and stabilized over time (**Figure 3C**). While transitions
176 between CSTs were common in both groups, transitions to CST1 were most common
177 in GERD, and CST1 was more stable in GERD patients than controls (**Figure 3D**).
178 Transitions to CST1 were associated with significant increases in absolute total
179 bacterial abundance (**Figure 3E**) and absolute abundance of the CST1-associated

180 genus *Prevotella* (**Figure 3F**). Conversely, transitions from CST1 were associated
181 with significant decreases in absolute total bacterial and *Prevotella* abundance.
182 Transitions between CST 2 and 3 were not associated with changes in absolute
183 bacterial abundance or absolute abundance of *Prevotella*. Instability in bacterial
184 abundance in GERD patients during the first year is thus driven by transitions to and
185 from CST1.

186 **GERD and CST as predictors of inflammation, ALAD, CLAD, and death**

187 We have previously reported differences in inflammatory cytokine levels, lung
188 allograft dysfunction and GERD in this cohort (1). We sought to assess whether the
189 addition of microbial community composition and density (CST and 16s rRNA gene
190 copy density) affected associations between allograft inflammation, ALAD and CLAD.

191 *Inflammation:* 16S density was strongly associated with individual proinflammatory
192 cytokine levels independently of GERD status (**Figure 4A**). Inflammation was defined
193 as having at least two out of four pro-inflammatory cytokines (IL-1 α , IL-1 β , IL-6, and
194 IL-8) in the 75th percentile, based on a similar previously published approach (12).
195 Samples with and without inflammation showed distinct distributions of
196 proinflammatory cytokine concentrations (**Figure S4A**). Inflammation was associated
197 with higher bacterial density at 3-, 6-, and 12-months post-transplant (**Figure S4B**).
198 Despite bacterial density being significantly higher in patients with CST1, the
199 proportion of patients with inflammation was significantly higher in patients with CST3
200 when compared to CST1 (Fisher's Exact OR [95% CI] = 2.3 [1.2-4.7], $P = 0.022$).
201 Although not significant, this CST3-inflammation relationship held when compared to
202 CST2 (OR [95% CI] = 2.1 [1.0-4.4], $P = 0.090$) as well. There were no differences in
203 the proportion of samples with inflammation from patients with and without GERD
204 within CST1 (Fisher's Exact OR [95% CI] = 1.6 [0.6-4.0], $P = 0.462$), CST2 (Fisher's

205 Exact OR [95% CI] = 1.6 [0.5-5.3], $P = 0.510$), and CST3 (Fisher's Exact OR [95%
206 CI] = 1.4 [0.5-3.9], $P = 0.596$) (**Figure 4B**). Comparison of individual proinflammatory
207 cytokines showed no differences between CSTs, with the exception of CST2 which
208 was associated with lower IL-8 concentrations compared to CST3 (**Figure S4C**).
209 Notably, while bacterial density/inflammation correlations were independent of GERD
210 diagnosis, they differed significantly by CST (**Figure 5**). All four proinflammatory
211 cytokine levels (IL-1 α , IL-1 β , IL-6 and IL-8) were associated with consistently lower
212 bacterial density for CST3 compared to CST1 (P -values for differences of regression
213 intercepts between CSTs were 0.044, 0.014, 0.022 and <0.0001 , respectively). This
214 may in part explain why, although GERD is associated with higher and more variable
215 bacterial density in the first transplant year, it is not associated with increased
216 inflammation in our cohort.

217 *ALAD, CLAD and Death.* At three months, a diagnosis of GERD was not significantly
218 associated with concurrent ALAD (Fisher's Exact OR [95% CI] = 1.4 [0.4-6.5], $P =$
219 0.692). However, ALAD was more common in patients with CST3 than with CST1
220 (Fisher's Exact OR [95% CI] = Infinity [1.5-Infinity], $P = 0.030$), but not different from
221 CST2 (Fisher's Exact OR [95% CI] = 1.8 [0.3-9.3], $P = 0.694$). A Cox proportional
222 hazards model was used to assess the association of GERD status and the number
223 of CST3 events at different intervals with time to CLAD and death, as shown in **Table**
224 **3**. One patient was excluded from this analysis due to missing metadata. GERD
225 status was not associated with CLAD. However, patients with higher cumulative
226 number of CST3 events at 6-, 9-, and 12-months post-transplant were more likely to
227 develop CLAD compared to CST1 or CST2, even when adjusted for sex, age at
228 transplant, CMV serostatus mismatch, and primary disease. This relationship also

229 held at 3 months post-transplant when adjusted for sex and CMV mismatch. GERD
 230 status and the number of CST3 events were not significantly associated with death.
 231

Outcome	Predictor	HR (95% CI)		HR (95% CI)		HR (95% CI)		HR (95% CI)		HR (95% CI)	
		GERD status (GERD) n=74, EV=21	P	CST3 samples at 3 mts n=67, EV=20	P	CST3 samples up to 6 mts n=72, EV=19	P	CST3 samples up to 9 mts n=70, EV=19	P	CST3 samples up to 12 mts n=69, EV=18	P
CLAD		0.55 (0.20-1.51)	0.24	1.99 (0.82-4.87)	0.12	2.01 (1.08-3.75)	0.02	1.77 (1.05-2.97)	0.03	1.67 (1.01-2.74)	0.04
	Adjusted for										
	Sex (M)	0.53 (0.19-1.46)	0.22	2.43 (0.96-6.13)	0.06	2.56 (1.29-5.07)	0.01	2.11 (1.21-3.68)	0.01	1.76 (1.08-2.85)	0.02
	Age at tx	0.41 (0.14-1.20)	0.11	1.87 (0.76-4.61)	0.17	1.88 (0.98-3.63)	0.05	1.68 (0.97-2.91)	0.06	1.57 (0.95-2.61)	0.07
	CMV mismatch (Yes)	0.55 (0.20-1.51)	0.24	2.20 (0.87-5.53)	0.09	2.05 (1.10-3.82)	0.02	1.76 (1.05-2.97)	0.03	1.67 (1.01-2.78)	0.04
	Primary disease	0.46 (0.16-1.29)	0.14	1.89 (0.75-4.76)	0.17	1.82 (0.96-3.46)	0.06	1.56 (0.93-2.62)	0.09	1.55 (0.94-2.54)	0.08
DEATH		0.37 (.11-1.28)	0.12	1.30 (0.50-3.38)	0.59	1.35 (0.66-2.73)	0.41	1.21 (0.66-2.22)	0.54	1.26 (0.72-2.23)	0.42
	Adjusted for										
	Sex (M)	0.36 (0.11-1.26)	0.11	1.51 (0.57-4.04)	0.41	1.50 (0.71-3.19)	0.29	1.31 (0.70-2.44)	0.39	1.29 (0.75-2.26)	0.36
	Age at tx	0.36 (0.10-1.29)	0.12	1.29 (0.49-3.40)	0.6	1.49 (0.69-3.22)	0.31	1.25 (0.66-2.35)	0.49	1.27 (0.71-2.26)	0.41
	CMV mismatch (Yes)	0.37 (0.11-1.29)	0.12	1.49 (0.55-4.04)	0.43	1.43 (0.72-2.86)	0.31	1.23 (0.68-2.21)	0.49	1.28 (0.74-2.21)	0.37
	Primary disease	0.36 (0.10-1.24)	0.11	1.22 (0.46-3.25)	0.7	1.51 (0.72-3.16)	0.27	1.24 (0.68-2.27)	0.48	1.24 (0.72-2.11)	0.44

232 **Table 3. Cox proportional hazards associated with GERD and events of**
 233 **community state type 3 (CST3).** GERD status and the number of CST3 events at
 234 different intervals were used to predict CLAD and death, and adjusted for potential
 235 confounders. HR = hazard ratios; G+ = GERD positive; mts = months; EV = events;
 236 tx = transplant; CMV = cytomegalovirus

237 **Association of Nissen Fundoplication with Inflammatory cytokines and**
 238 **bacterial density.**

239 In a cohort of 10-patients who underwent Nissen fundoplication for symptomatic
 240 GERD, we assessed pre/post-procedure bacterial load and pro-inflammatory
 241 cytokine levels in BALF supernatants. Similarly to our previous report (1), significant
 242 decreases in pro-inflammatory cytokines were observed after fundoplication (**Figure**
 243 **6A**). While no significant changes were observed in overall bacterial loads pre and

244 post fundoplication, individuals with the greatest decreases in inflammatory cytokines
245 also had the greatest decreases in bacterial density as measured by 16S rRNA gene
246 qPCR, and had the highest baseline densities of the CST1-associated genus
247 *Prevotella*. This suggests that fundoplication may have direct or indirect effects on
248 the allograft microbiota that vary by baseline community composition (**Figure 6B**).

249 **Discussion.**

250 This study is the first to systematically compare the allograft microbiota in lung
251 transplant recipients with and without GERD. We were able to compare the
252 relationship between microbial community composition, inflammation, ALAD and
253 CLAD in lung allograft recipients with and without GERD, while also assessing the
254 effects of anti-reflux surgery on allograft bacterial density. We believe we add the
255 following observations to our understanding of allograft microbiota-host associations
256 in the context of GERD:

- 257 1) The strongest feature of allograft community composition is the underlying
258 compositional clustering of the allograft microbiota. We observed three major
259 clusters, which we referred to as CST 1-3, with no significant observed
260 microbial community compositional differences between GERD cases and
261 controls within these clusters;
- 262 2) The proportion of samples with these CSTs differed between GERD and
263 control groups, with the high-density, oropharyngeal-taxa-enriched CST1
264 being more common in GERD than in no-GERD controls;
- 265 3) GERD was associated with a more variable community composition and
266 bacterial abundance in the first-year post-transplant, with more frequent
267 transitions between lower density CST2/3 and CST1 in GERD cases than
268 controls;

- 269 4) CST-inflammation associations exceeded any association between GERD
270 status and inflammation in this cohort;
- 271 5) The CST most common in lung allograft recipients with GERD (CST1) was
272 associated with lower per-bacteria inflammatory cytokine levels than the
273 pathogen-dominated CST3;
- 274 6) Models used to predict inflammation, ALAD and CLAD revealed CST –
275 particularly CST3, but not GERD-status associations;
- 276 7) Nissen fundoplication was associated with strongly correlated decreases in
277 bacterial load and pro-inflammatory cytokines, especially in individuals with
278 high pre-fundoplication density of the CST1-associated genus *Prevotella*.

279 Our observation of a clear structure underlying beta-diversity of the lung allograft
280 confirms the results of others (5, 8). We applied the term ‘community state types’ to
281 describe these distinct clusters as is commonly done to describe the microbiota of the
282 female genital tract (13), which has a similarly limited number of taxa and discrete
283 compositional clustering compared to other human sample types such as gut/stool.
284 We note that there are taxonomic differences in the clusters we observed compared
285 to those reported by others, which may in part be due to technical factors (e.g.
286 sequencing methods and sequence variant annotation) or differences in methods to
287 identify and remove taxa suspected to be reagent contaminants, which is especially
288 consequential for low density samples in CST2 (14). Nonetheless, we noted a very
289 consistent composition for CST1, dominated by oropharyngeal taxa and CST3
290 characterized by the prevalence and relative abundance of putative pathogens. Thus,
291 we feel our findings with respect to community composition are likely to be
292 generalizable to other cohorts.

293 We were unable to assess whether enrichment for CST1 amongst individuals with
294 GERD was due to actual aspiration of refluxed oropharyngeal content in this
295 observational study. However, we found that decreases in inflammatory cytokines
296 after Nissen fundoplication were greatest in individuals with significant decreases in
297 bacterial density and high initial *Prevotella* absolute abundance in BALF supernatant.
298 This is consistent with a model in which GERD is associated with aspiration of
299 oropharyngeal taxa, leading to inflammation. This hypothesis requires both
300 replication and experimental validation.

301 CST was not significantly associated with bile acid concentrations, although we
302 cannot exclude the possibility that this association exists and future datasets can
303 reassess this in larger cohorts. Conjugated bile acids, like TCA and GCA, have been
304 associated with poor clinical outcomes and bacterial infections (1, 15). This may
305 explain the weak trends in CST1 and CST3, CSTs that contain aspiration-related
306 microbes and pathogens.

307 A similar number of patients with and without GERD had CST3, suggesting that this
308 CST arises independently of reflux. CST3 was characterized by increased relative
309 abundance of *Pseudomonas* and *Staphylococcus*, two taxa with known pathogenic
310 species. Despite CST1 being enriched for GERD and having higher bacterial density,
311 CST1 and CST2 were similarly associated with decreased rates of inflammation,
312 CLAD, and ALAD compared to CST3. The association of pathogen-communities,
313 inflammation and host status replicates the findings of others (5, 8). Importantly, our
314 study highlights how the relationship between GERD and clinical outcomes may be
315 confounded by the underlying microbial composition of the lung, since the GERD-
316 associated CST1 correlated with less inflammation, ALAD and CLAD. Future studies
317 assessing relationships between GERD and host status or prognosis should control

318 for the potential confounding by underlying CST or analyse it as an interacting
319 variable.

320 Our study has several important limitations. The primary analysis was based on a
321 case-control, retrospective, single-centre cohort, requiring validation. In addition, the
322 cohort was composed of patients with clear GERD or no-GERD testing results,
323 including individuals with numbers of reflux episodes in 24 hours of >48 or <23. Our
324 findings, therefore, may not apply to individuals with intermittent or less
325 frequent/severe reflux. Importantly, this limitation would be expected to exaggerate
326 the differences between cases and controls, and thus our observation that underlying
327 CST structure is more strongly associated with host status and CLAD than GERD is
328 likely true, as our cohort represents an 'extreme' GERD phenotype. In addition, we
329 did not comprehensively assess the relationships between CST, GERD and a wide
330 array of soluble or other host factors in BALF, and restricted our analysis to four pro-
331 inflammatory cytokines, ALAD and CLAD. Associations between GERD and other
332 soluble or host-derived factors in BALF may be present. Finally, our small Nissen
333 fundoplication cohort was assessed without sequencing, since we had only BALF
334 supernatant available, which is compositionally different from BALF pellets or raw
335 BALF (uncentrifuged or fractionated).

336 In summary, increased bacterial density and taxonomic composition dominated by
337 oropharyngeal taxa is associated with GERD. This microbial state was not associated
338 with increased risk of CLAD or death and surgical treatment of GERD showed
339 correlation between changes in bacterial density and levels of pro-inflammatory
340 cytokines. Similarly to what was recently published, we showed that a pathogen-
341 dominated community independent of GERD status is associated with increased risk
342 of lung allograft dysfunction. Future studies should investigate the exact effect of

343 GERD treatment and whether it promotes or protects from colonization of the lung
344 ecological niche by CLAD-associated microbial communities.

345 **Methods.**

346 **Cohort design.** This study was approved by the Toronto University Health Network
347 Research Ethics Board (REB#15-9698-AE) and the Duke University Internal Review
348 Board (Pro00013378). The cohorts were derived from two previously published
349 cohorts, leveraging the cytokine and bile acid data that was generated by this prior
350 study (1).

351 GERD Cohort (Figure S1): Patients from the previously published GERD cohort were
352 included if they had at least one available raw (unprocessed) BALF sample obtained
353 in the first-year post-transplant (1). In summary, this was a nested case-control
354 cohort, drawn from all adults who underwent bilateral or single lung transplantation at
355 Toronto General Hospital between 2010 and 2015. Patients were included if they had
356 24-hour pH/impedance probe testing and at least one raw and supernatant BALF
357 sample collected and preserved in the first-year post-transplant. Patients whose 24-
358 hour pH/impedance study showed ≥ 48 reflux episodes were included as GERD
359 cases. For no-GERD controls, patients with < 23 reflux episodes were excluded if
360 they reported symptoms of reflux during the study or had underlying disease
361 commonly associated with GERD (e.g. scleroderma, hiatal hernia, Barrett's
362 esophagus, history of Nissen fundoplication or pyloroplasty), and matched 2:1 to the
363 GERD patients by transplant type (single vs. bilateral). For the selected patients,
364 available BALF samples closest to the 3-, 6-, 9-, and 12-month time points of
365 surveillance bronchoscopies were obtained.

366 Nissen Cohort: Patients from the previously published Nissen cohort were included if
367 they had sufficient pre- and post-Nissen BALF supernatant remaining for analysis (1).
368 In summary, this was a retrospective cohort drawn from all adults who underwent
369 bilateral lung transplantation at Duke University Medical Center between 2005 and
370 2008. 10 patients were included who underwent Nissen fundoplication within 6
371 months post-transplant and had available paired BALF samples obtained within 3
372 months before and after Nissen fundoplication.

373 ***Clinical Standards of Care and Definitions.*** Standard of care for lung transplant
374 recipients was delivered as described previously by the Toronto and Duke programs
375 (16, 17). In the first year after lung transplant, both programs performed surveillance
376 bronchoscopies to obtain BALF and transbronchial biopsies at pre-specified time
377 points (Toronto: 0.5, 1.5, 3, 6, 9, 12 months; Duke: 1, 3, 6, 9, 12 months) and as
378 clinically indicated. During the study period, the Toronto BAL protocol was to instill 50
379 mL of normal saline twice, while the Duke protocol consisted of one 60 mL instillation,
380 the right middle lobe being the default location at both institutions.

381 At Toronto, patients were treated with proton pump inhibitors based on
382 symptoms and routine pH/impedance studies performed at 3 months post-transplant.
383 No patients in the cohort underwent Nissen fundoplication in the first post-transplant
384 year.

385 At Duke, patients were treated with proton pump inhibitors regardless of reflux
386 studies. Patients underwent routine 24-hour pH monitor prior to transplantation, and
387 repeat testing post-transplant if the pre-transplant study was negative. Any positive
388 study, defined as <0.9% proximal acid contact time and/or <4.2% distal acid contact
389 time, led to referral for Nissen fundoplication.

390 Acute lung allograft dysfunction (ALAD) was defined as a $\geq 10\%$ decline in
391 measured forced expiratory volume in 1 second (FEV1) compared to the higher of
392 the two preceding FEV1 measurements. CLAD was defined as per latest consensus
393 report from the International Society for Heart and Lung Transplantation (2).

394 **BAL sample processing.** In Toronto, raw BALF samples were aliquoted and stored
395 at $-80\text{ }^{\circ}\text{C}$. The remaining BALF was centrifuged at 3184 g for 20 minutes and the
396 supernatant was also stored at $-80\text{ }^{\circ}\text{C}$. At Duke, BALF samples were centrifuged at
397 1750 g for 10 minutes at 4°C and the supernatant was stored at $-80\text{ }^{\circ}\text{C}$.

398 **Analysis of BALF supernatant samples.** Markers of innate immune activation,
399 including IL-1 α , IL-1 β , IL-6, and IL-8, were measured in the BALF supernatant using
400 a custom-designed multiplex assay (R&D), as reported previously (1). Taurocholic
401 acid (TCA), one of the most abundant bile acids, was measured using LC-MS/MS
402 mass spectrometry, as reported previously (1).

403 **DNA isolation and quantification from BALF samples.** Nucleic acids were isolated
404 from 250 μl of raw BALF samples (Toronto) or BALF supernatant (Duke) using a
405 PowerSoil DNA isolation kit (MO-BIO; Carlsbad, CA, USA) following the
406 manufacturer's instructions except for the elution step which was done in 60 μl
407 purified water. Densities were measured using a 16S quantitative polymerase chain
408 reaction (qPCR;(18)) and a standard (*Pseudomonas aeruginosa* str. PAO1), and the
409 number of 16S copies /ml was inferred using the URI Genomics & Sequencing
410 Center online calculator (<http://cels.uri.edu/gsc/cndna.html>). 16S qPCR primers and
411 conditions are described in the online supplement. qPCR reactions were carried out
412 in a volume of 11 μl using the TaqMan Gene Expression Master Mix (Applied
413 Biosystems, Foster City, CA, USA) according to the manufacturer's protocol.

414 **16S rRNA gene sequencing of DNA from raw BALF samples.** The V4
415 hypervariable region of the 16S rRNA gene is amplified using a universal forward
416 sequencing primer and a uniquely barcoded reverse sequencing primer to allow for
417 multiplexing (19). Amplification reactions are performed using 12.5 µL of KAPA2G
418 Robust HotStart ReadyMix (KAPA Biosystems), 1.5 µL of 10 µM forward and reverse
419 primers, 7.5 µL of sterile water and 2 µL of DNA. The V4 region was amplified by
420 cycling the reaction at 95°C for 3 minutes, 28x cycles of 95°C for 15 seconds, 50°C
421 for 15 seconds and 72°C for 15 seconds, followed by a 5-minute 72°C extension. All
422 amplification reactions were done in triplicate, checked on a 1% agarose TBE gel,
423 and then pooled to reduce amplification bias. Pooled triplicates were quantified using
424 PicoGreen (Thermo Fisher) and combined by even concentrations. The library was
425 then purified using Ampure XP beads and loaded on to the Illumina MiSeq for
426 sequencing, according to manufacturer instructions (Illumina, San Diego, CA).
427 Sequencing is performed using the V2 (150bp x 2) chemistry. DNA from a single-
428 species, *Pseudomonas aeruginosa*, from a mock community (Zymo Microbial
429 Standard: <https://www.zymoresearch.de/zymbiomics-community-standard>), and a
430 template-free negative control were included in the sequencing run. Two individual
431 libraries were prepared and sequenced from each sample.

432 **Analysis of the bacterial microbiome.** The UNOISE pipeline, available through
433 USEARCH v11.0.667 and vsearch v2.10.4, was used for sequence analysis (20-22).
434 The last base was removed from all sequences using cutadapt v.1.18. Sequences
435 were assembled and quality trimmed using `-fastq_mergepairs` with a `-fastq_trunctail`
436 set at 5, a `-fastq_minqual` set at 5, and minimum and maximum assemble lengths set
437 at 243 and 263 (+/- 10 from the mean) base pairs. Sequences were first de-replicated
438 and sorted to remove singletons, then denoised and chimeras were removed using

439 the unoise3 command. Assembled sequences were mapped back to the chimera-
440 free denoised sequences at 97% identity OTUs. Taxonomy assignment was
441 executed using SINTAX (23) available through USEARCH, and the UNOISE
442 compatible Ribosomal Database Project (RDP) database version 16, with a minimum
443 confidence cutoff of 0.8 (24). OTU sequences were aligned using align_seqs.py
444 v.1.9.1 through QIIME1 (25). Sequences that did not align were removed from the
445 dataset and a phylogenetic tree of the filtered aligned sequence data was made
446 using FastTree (26).

447 **Post-profiling filtering approaches.** 16S rRNA gene sequences from contaminants
448 is a recurrent issue when analysing BALF samples (27) and we controlled for
449 sequencing contaminants as described in Schneeberger *et al.* (14). Briefly, OTUs
450 which were negatively correlated with bacterial density measured with qPCR across
451 all samples were considered as contaminants. In addition, OTUs which were only
452 present in one sequencing replicate were removed.

453 **Statistical analysis.** Bray-Curtis dissimilarity indices were calculated using the
454 “dissimilarity” function from the Vegan R package version 2.5-2 (28). The metaMDS
455 function was used with the options “k=6” and “try=500” to generate NMDS ordination
456 plots. Most important features for CST classification were identified using the random
457 forest model from the randomForest package version 4.6-14 based on (29) and
458 coordinates from the most important classification features (= genus) were extracted
459 manually from the metaMDS output. The correlation coefficients assessing stability in
460 bacterial density were estimated by generalized estimating equations (GEE) from the
461 geepack R package version 1.3-2 (30). Odds ratios and independence were
462 calculated using the Fisher’s exact test. Taxonomic differences between CSTs were
463 identified using the LEfSe pipeline (31). Mann-Whitney tests, Wilcoxon signed rank

464 tests, and Spearman correlations were calculated using XLSTAT 2019 (Addinsoft:
465 Paris, France). Regression analyses were conducted in Graphpad Prism version
466 9.0.0 (San Diego, CA, USA). Plots were generated using OriginPro 2017
467 (Northampton, MA, USA) and the R packages ggplot2 version 3.0.0 (32), reshape2
468 version 1.4.3 (33), and ggalluvial version 0.12.1 based on (34).

469

470 **Availability of data and material**

471 Sequence data that support the findings of this study have been deposited in the
472 NCBI Short Read Archive with the primary accession code PRJNA754787.

473

474 **Funding**

475 This study received financial support from the Canadian Institutes for Health
476 Research (PJT149057, to BC and TM); from the Multi-Organ Transplant Program at
477 the University Health Network (to BC and TM); from the National Institutes of Health
478 (NIH)/National Institute of Allergy and Infectious Diseases (NIAID), Clinical Trials in
479 Organ Transplantation (CTOT-20) Ancillary Study Fund (to TM); from the
480 Comprehensive Research Experience for Medical Students (CREMS) Program (to
481 CYKZ), and from the Cystic Fibrosis Foundation (to BC and TM).

482

483 **Author contributions**

484 **PHHS:** research design, experiments (microbial culture, pre-sequencing workup,
485 concentration, DNA isolation, 16S qPCR quantification, taxonomic profiling),
486 statistical analyses, figures generation, writing of the initial manuscript, manuscript

487 editing; **CYKZ**: cohort design, cohort organization, clinical data collection, patient
488 phenotyping, sample organization, multiplex data analysis, writing and editing
489 manuscript; **JS**: statistical analyses, figures generation, writing of the initial
490 manuscript, manuscript editing; **BC** and **WX**: statistical analyses, manuscript editing;
491 **YL**: experiments (pre-sequencing workup, DNA isolation, qPCR), manuscript editing;
492 **ZW**: sample organization, experiments for Nissen cohort (DNA isolation, 16S qPCR
493 quantification), qPCR data analysis; **ERN** and **NY**: sample processing, manuscript
494 editing **MA**: cohort design, cohort organization, clinical data collection, patient
495 phenotyping; **KB**: Multiplex cytokine assays; **RR**: clinical data collection and curation;
496 **CWF**: cohort organization, clinical data collection, sample organization (for Nissen
497 cohort); **SMP** and **JLT**: cohort design, clinical data collection, patient phenotyping;
498 **TM**: research design, project supervision, cohort design, data analysis, manuscript
499 writing and editing; **BC**: research design, project supervision, data analysis,
500 manuscript writing and editing.

501

502 **Acknowledgements**

503 The authors thank the Centre for the Analysis of Genome Evolution and Function
504 (CAGEF) for providing support in the sequencing experiments as well as
505 bioinformatics support for the taxonomic profiling. The authors also thank the Toronto
506 Lung Transplant Program Biobank team for helping with sample collection and
507 retrieval.

508

509 **Competing Interests**

510 The authors declare that they have no competing interests

511

512 **FIGURES:**

513 **Figure 1. Composition of the lung microbiota in post-transplant patients with**
514 **and without GERD. A.** Classification of BALF samples based on Bray-Curtis
515 dissimilarity measure. **B.** Non-metric multidimensional scaling plots based on Bray-
516 Curtis dissimilarity measure comparing spatial ordination of GERD vs no-GERD
517 patients, CST1-3 samples, and showing genera contributing most to this
518 classification system. **C.** Proportion of CSTs by GERD status. GERD =
519 gastroesophageal reflux disease; BALF = bronchoalveolar lavage fluid; CST (1-3) =
520 community state types (1 to 3).

521 **Figure 2. CST-specific microbial features. A.** Genera enriched in each CST,
522 identified using the LefSe (Linear discriminant analysis (LDA) Effect Size) pipeline. A
523 higher LDA score indicates a higher difference between groups. **B.** Comparison of
524 total bacterial density based on 16S rRNA gene copies/mL BALF and *Prevotella*-
525 specific quantitative polymerase chain reaction, by CST. **C.** Comparison of alpha
526 diversity indices, by CST. Group comparison was tested using Mann-Whitney tests.
527 CST = community state type; BALF = bronchoalveolar lavage fluid.

528 **Figure 3. Longitudinal analysis of the lung microbiota 1 year after**
529 **transplantation. A.** Comparison of total bacterial density variation by GERD status.
530 **B.** Comparison of alpha diversity indices changes over time by GERD status. **C.**
531 Patient-specific variation measured using the Bray-Curtis dissimilarity measure
532 between consecutive samples, by GERD status. **D.** Transitions of CSTs between 3-6-
533 , 6-9-, and 9-12-months post-transplant, by GERD status. **E.** Changes in total
534 bacterial density associated with transition to the different CSTs. **F.** Changes in
535 *Prevotella* density associated with CST transitions.

536 **Figure 4. Associations between GERD status, microbial composition and**
537 **density, and inflammation. A.** Linear regression analysis of total bacterial density
538 and individual pro-inflammatory cytokines. **B.** Proportion of samples with
539 inflammation - defined by two or more cytokines in the top 75th percentile -, by CST
540 and further stratified by GERD status.

541 **Figure 5.** Association between total bacterial density and individual pro-inflammatory
542 cytokines, stratified by community state type (CST1 = green; CST2 = yellow; CST3 =
543 red).

544 **Figure 6. Pre/Post-Nissen fundoplication comparison of bacterial density and**
545 **individual cytokines. A.** Changes in total bacterial density and cytokines, by patient.
546 **B.** Regression between individual cytokines and total bacterial density, weighted by
547 pre-Nissen density of the CST1-associated genus, *Prevotella*.

548

549 **Bibliography**

- 550 1. Zhang CYK, Ahmed M, Huszti E, Levy L, Hunter SE, Boonstra KM, Moshkelgosha
551 S, Sage AT, Azad S, Zamel R. Bronchoalveolar bile acid and inflammatory
552 markers to identify high-risk lung transplant recipients with reflux and
553 microaspiration. *The Journal of Heart and Lung Transplantation* 2020; 39: 934-
554 944.
- 555 2. Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, Ensor
556 CR, Gottlieb J, Hachem RR, Lama V. Chronic lung allograft dysfunction:
557 Definition, diagnostic criteria, and approaches to treatment—A consensus
558 report from the Pulmonary Council of the ISHLT. *The Journal of Heart and*
559 *Lung Transplantation* 2019; 38: 493-503.
- 560 3. Razia D, Mittal S, Bremner R, Bansal S, Ravichandran R, Smith M, Walia R,
561 Mohanakumar T, Tokman S. Pretransplant GERD-Induced Immune Response
562 Predisposes to CLAD. *The Journal of Heart and Lung Transplantation* 2021;
563 40: S59.
- 564 4. King BJ, Iyer H, Leidi AA, Carby MR. Gastroesophageal reflux in bronchiolitis
565 obliterans syndrome: a new perspective. *The Journal of heart and lung*
566 *transplantation* 2009; 28: 870-875.


- 567 5. Combs MP, Wheeler DS, Luth JE, Falkowski NR, Walker NM, Erb-Downward JR,
568 Lama VN, Dickson RP. Lung microbiota predict chronic rejection in healthy
569 lung transplant recipients: a prospective cohort study. *The Lancet Respiratory*
570 *Medicine* 2021; 9: 601-612.
- 571 6. Willner DL, Hugenholtz P, Yerkovich ST, Tan ME, Daly JN, Lachner N, Hopkins
572 PM, Chambers DC. Reestablishment of recipient-associated microbiota in the
573 lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome.
574 *American journal of respiratory and critical care medicine* 2013; 187: 640-647.
- 575 7. Royer P-J, Olivera-Botello G, Koutsokera A, Aubert J-D, Bernasconi E, Tissot A,
576 Pison C, Nicod L, Boissel J-P, Magnan A. Chronic lung allograft dysfunction: a
577 systematic review of mechanisms. *Transplantation* 2016; 100: 1803-1814.
- 578 8. Mouraux S, Bernasconi E, Pattaroni C, Koutsokera A, Aubert J-D, Claustre J,
579 Pison C, Royer P-J, Magnan A, Kessler R. Airway microbiota signals anabolic
580 and catabolic remodeling in the transplanted lung. *Journal of Allergy and*
581 *Clinical Immunology* 2018; 141: 718-729. e717.
- 582 9. Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung:
583 new conceptual models of pulmonary microbiology and pneumonia
584 pathogenesis. *The lancet Respiratory medicine* 2014; 2: 238-246.
- 585 10. Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Beck JM, Huffnagle
586 GB, Curtis JL. Spatial variation in the healthy human lung microbiome and the
587 adapted island model of lung biogeography. *Annals of the American Thoracic*
588 *Society* 2015; 12: 821-830.
- 589 11. Dickson RP, Erb-Downward JR, Huffnagle GB. Homeostasis and its disruption in
590 the lung microbiome. *American Journal of Physiology-Lung Cellular and*
591 *Molecular Physiology* 2015; 309: L1047-L1055.
- 592 12. Masson L, Passmore J-AS, Liebenberg LJ, Werner L, Baxter C, Arnold KB,
593 Williamson C, Little F, Mansoor LE, Naranbhai V. Genital inflammation and the
594 risk of HIV acquisition in women. *Clinical Infectious Diseases* 2015; 61: 260-
595 269.
- 596 13. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S,
597 Gorle R, Russell J, Tacket CO. Vaginal microbiome of reproductive-age
598 women. *Proceedings of the National Academy of Sciences* 2011; 108: 4680-
599 4687.
- 600 14. Schneeberger PHH, Prescod J, Levy L, Hwang D, Martinu T, Coburn B.
601 Microbiota analysis optimization for human bronchoalveolar lavage fluid.
602 *Microbiome* 2019; 7: 141.
- 603 15. Urso A, Leiva-Juárez MM, Briganti DF, Aramini B, Benvenuto L, Costa J,
604 Nandakumar R, Gomez EA, Robbins HY, Shah L. Aspiration of Conjugated
605 Bile Acids Predicts Adverse Lung Transplant Outcomes and Correlates with
606 Airway Lipid and Cytokine Dysregulation. *The Journal of Heart and Lung*
607 *Transplantation* 2021.
- 608 16. Tinckam K, Keshavjee S, Chaparro C, Barth D, Azad S, Binnie M, Chow C, de
609 Perrot M, Pierre A, Waddell T. Survival in sensitized lung transplant recipients

- 610 with perioperative desensitization. *American Journal of Transplantation* 2015;
611 15: 417-426.
- 612 17. Gray AL, Mulvihill MS, Hartwig MG. Lung transplantation at Duke. *Journal of*
613 *thoracic disease* 2016; 8: E185.
- 614 18. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load
615 by real-time PCR using a broad-range (universal) probe and primers set.
616 *Microbiology* 2002; 148: 257-266.
- 617 19. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N,
618 Owens SM, Betley J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G,
619 Knight R. Ultra-high-throughput microbial community analysis on the Illumina
620 HiSeq and MiSeq platforms. *The ISME journal* 2012; 6: 1621-1624.
- 621 20. Edgar RC. Search and clustering orders of magnitude faster than BLAST.
622 *Bioinformatics* 2010; 26: 2460-2461.
- 623 21. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon
624 reads. *Nat Methods* 2013; 10: 996-998.
- 625 22. Edgar RC. UNOISE2: improved error-correction for Illumina 16S and ITS
626 amplicon sequencing. *BioRxiv* 2016: 081257.
- 627 23. Edgar R. SINTAX: a simple non-Bayesian taxonomy classifier for 16S and ITS
628 sequences. *BioRxiv* 2016: 074161.
- 629 24. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid
630 assignment of rRNA sequences into the new bacterial taxonomy. *Applied and*
631 *environmental microbiology* 2007; 73: 5261-5267.
- 632 25. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK,
633 Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D,
634 Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M,
635 Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenkov
636 T, Zaneveld J, Knight R. QIIME allows analysis of high-throughput community
637 sequencing data. *Nat Methods* 2010; 7: 335-336.
- 638 26. Price MN, Dehal PS, Arkin AP. FastTree: computing large minimum evolution
639 trees with profiles instead of a distance matrix. *Molecular biology and evolution*
640 2009; 26: 1641-1650.
- 641 27. Carney SM, Clemente JC, Cox MJ, Dickson RP, Huang YJ, Kitsios GD, Kloepfer
642 KM, Leung JM, LeVan TD, Molyneaux PL. Methods in lung microbiome
643 research. *American journal of respiratory cell and molecular biology* 2020; 62:
644 283-299.
- 645 28. Dixon P. VEGAN, a package of R functions for community ecology. *Journal of*
646 *Vegetation Science* 2003; 14: 927-930.
- 647 29. Breiman L. Bagging predictors. *Machine learning* 1996; 24: 123-140.
- 648 30. Højsgaard S, Halekoh U, Yan J. The R package geepack for generalized
649 estimating equations. *Journal of statistical software* 2005; 15: 1-11.
- 650 31. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower
651 C. Metagenomic biomarker discovery and explanation. *Genome biology* 2011;
652 12: 1-18.
- 653 32. Wickham H. ggplot2: elegant graphics for data analysis. Springer; 2016.


- 654 33. Wickham H. Reshaping data with the reshape package. *Journal of Statistical*
655 *Software* 2007; 21: 1-20.
- 656 34. Wickham H. A layered grammar of graphics. *Journal of Computational and*
657 *Graphical Statistics* 2010; 19: 3-28.
- 658

FIGURE 1

A



B



C






FIGURE 2

A



B



C




FIGURE 3





FIGURE 4

A



B




FIGURE 5





FIGURE 6

A



B




FIGURE S1




FIGURE S2



FIGURE S3




FIGURE S4

